Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?

Semra Ince, Richard Laforest, Malak Itani, Vikas Prasad, Paul-Robert Derenoncourt, John P Crandall, Saeed Ashrafinia, Anne M Smith, Richard L Wahl, Tyler J Fraum
{"title":"Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?","authors":"Semra Ince, Richard Laforest, Malak Itani, Vikas Prasad, Paul-Robert Derenoncourt, John P Crandall, Saeed Ashrafinia, Anne M Smith, Richard L Wahl, Tyler J Fraum","doi":"10.2967/jnumed.123.266469","DOIUrl":null,"url":null,"abstract":"<p><p>In oncologic PET, the SUV and standardized uptake ratio (SUR) of a viable tumor generally increase during the postinjection period. In contrast, the net influx rate (<i>K<sub>i</sub></i> ), which is derived from dynamic PET data, should remain relatively constant. Uptake-time-corrected SUV (cSUV) and SUR (cSUR) have been proposed as uptake-time-independent, static alternatives to <i>K<sub>i</sub></i> Our primary aim was to quantify the intrascan repeatability of <i>K<sub>i</sub></i> , SUV, cSUV, SUR, and cSUR among malignant lesions on PET/CT. An exploratory aim was to assess the ability of cSUR to estimate <i>K<sub>i</sub></i> <b>Methods:</b> This prospective, single-center study enrolled adults undergoing standard-of-care oncologic PET/CT. SUV and <i>K<sub>i</sub></i> images were reconstructed from dynamic PET data obtained before (∼35-50 min after injection) and after (∼75-90 min after injection) standard-of-care imaging. Tumors were manually segmented. Quantitative metrics were extracted. cSUVs and cSURs were calculated for a 60-min postinjection reference uptake time. The magnitude of the intrascan test-retest percent change (test-retest |%Δ|) was calculated. Coefficients of determination (<i>R</i> <sup>2</sup>) and intraclass correlation coefficients (ICC) were also computed. Differences between metrics were assessed via the Wilcoxon signed-rank test (α, 0.05). <b>Results:</b> This study enrolled 78 subjects; 41 subjects (mean age, 63.8 y; 24 men) with 116 lesions were analyzed. For both tracers, SUV<sub>max</sub> and maximum SUR (SUR<sub>max</sub>) had large early-to-late increases (i.e., poor intrascan repeatability). Among [<sup>18</sup>F]FDG-avid lesions (<i>n</i> = 93), there were no differences in intrascan repeatability (median test-retest |%Δ|; ICC) between the maximum <i>K<sub>i</sub></i> (<i>K<sub>i</sub></i> <sub>,max</sub>) (13%; 0.97) and either the maximum cSUV (cSUV<sub>max</sub>) (12%, <i>P</i> = 0.90; 0.96) or the maximum cSUR (cSUR<sub>max</sub>) (13%, <i>P</i> = 0.67; 0.94). For DOTATATE-avid lesions (<i>n</i> = 23), there were no differences in intrascan repeatability between the <i>K<sub>i</sub></i> <sub>,max</sub> (11%; 0.98) and either the cSUV<sub>max</sub> (13%, <i>P</i> = 0.41; 0.98) or the cSUR<sub>max</sub> (11%, <i>P</i> = 0.08; 0.94). The SUV<sub>max</sub>, cSUV<sub>max</sub>, SUR<sub>max</sub>, and cSUR<sub>max</sub> were all strongly correlated with the <i>K<sub>i</sub></i> <sub>,max</sub> for both [<sup>18</sup>F]FDG (<i>R</i> <sup>2</sup>, 0.81-0.92) and DOTATATE (<i>R</i> <sup>2</sup>, 0.88-0.96), but the cSUR<sub>max</sub> provided the best agreement with the <i>K<sub>i</sub></i> <sub>,max</sub> across early-to-late time points for [<sup>18</sup>F]FDG (ICC, 0.69-0.75) and DOTATATE (ICC, 0.90-0.91). <b>Conclusion:</b> <i>K<sub>i</sub></i> <sub>,max</sub>, cSUV<sub>max</sub>, and cSUR<sub>max</sub> had low uptake time dependence compared with SUV<sub>max</sub> and SUR<sub>max</sub> The <i>K<sub>i</sub></i> <sub>,max</sub> can be predicted from cSUR<sub>max</sub>.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1349-1356"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372261/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.123.266469","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In oncologic PET, the SUV and standardized uptake ratio (SUR) of a viable tumor generally increase during the postinjection period. In contrast, the net influx rate (Ki ), which is derived from dynamic PET data, should remain relatively constant. Uptake-time-corrected SUV (cSUV) and SUR (cSUR) have been proposed as uptake-time-independent, static alternatives to Ki Our primary aim was to quantify the intrascan repeatability of Ki , SUV, cSUV, SUR, and cSUR among malignant lesions on PET/CT. An exploratory aim was to assess the ability of cSUR to estimate Ki Methods: This prospective, single-center study enrolled adults undergoing standard-of-care oncologic PET/CT. SUV and Ki images were reconstructed from dynamic PET data obtained before (∼35-50 min after injection) and after (∼75-90 min after injection) standard-of-care imaging. Tumors were manually segmented. Quantitative metrics were extracted. cSUVs and cSURs were calculated for a 60-min postinjection reference uptake time. The magnitude of the intrascan test-retest percent change (test-retest |%Δ|) was calculated. Coefficients of determination (R 2) and intraclass correlation coefficients (ICC) were also computed. Differences between metrics were assessed via the Wilcoxon signed-rank test (α, 0.05). Results: This study enrolled 78 subjects; 41 subjects (mean age, 63.8 y; 24 men) with 116 lesions were analyzed. For both tracers, SUVmax and maximum SUR (SURmax) had large early-to-late increases (i.e., poor intrascan repeatability). Among [18F]FDG-avid lesions (n = 93), there were no differences in intrascan repeatability (median test-retest |%Δ|; ICC) between the maximum Ki (Ki ,max) (13%; 0.97) and either the maximum cSUV (cSUVmax) (12%, P = 0.90; 0.96) or the maximum cSUR (cSURmax) (13%, P = 0.67; 0.94). For DOTATATE-avid lesions (n = 23), there were no differences in intrascan repeatability between the Ki ,max (11%; 0.98) and either the cSUVmax (13%, P = 0.41; 0.98) or the cSURmax (11%, P = 0.08; 0.94). The SUVmax, cSUVmax, SURmax, and cSURmax were all strongly correlated with the Ki ,max for both [18F]FDG (R 2, 0.81-0.92) and DOTATATE (R 2, 0.88-0.96), but the cSURmax provided the best agreement with the Ki ,max across early-to-late time points for [18F]FDG (ICC, 0.69-0.75) and DOTATATE (ICC, 0.90-0.91). Conclusion: Ki ,max, cSUVmax, and cSURmax had low uptake time dependence compared with SUVmax and SURmax The Ki ,max can be predicted from cSURmax.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
普通肿瘤 PET/CT 群体中肿瘤活性的定量评估:哪种指标能将示踪剂摄取时间依赖性降至最低?
在肿瘤正电子发射计算机断层显像中,有活力肿瘤的 SUV 和标准化摄取比(SUR)通常在注射后期间增加。相比之下,根据动态 PET 数据得出的净流入率(Ki)应保持相对恒定。我们的主要目的是量化 PET/CT 恶性病变中 Ki、SUV、cSUV、SUR 和 cSUR 的扫描内重复性。探索性目的是评估 cSUR 估算 Ki 的能力:这项前瞻性单中心研究招募了接受标准治疗肿瘤 PET/CT 的成人。根据标准治疗成像前(注射后 35-50 分钟)和成像后(注射后 75-90 分钟)获得的动态 PET 数据重建 SUV 和 Ki 图像。对肿瘤进行人工分割。以注射后 60 分钟为参考摄取时间,计算 cSUV 和 cSUR。计算扫描内测试-重测百分比变化(测试-重测 |%Δ|)的幅度。还计算了测定系数(R 2)和类内相关系数(ICC)。指标之间的差异通过 Wilcoxon 符号秩检验进行评估(α,0.05)。结果本研究共纳入 78 名受试者,对 41 名受试者(平均年龄 63.8 岁;男性 24 名)的 116 个病灶进行了分析。两种示踪剂的 SUVmax 和最大 SUR(SURmax)在早期到晚期都有较大的增长(即级内重复性较差)。在[18F]FDG-avid病变(n = 93)中,最大Ki (Ki ,max) (13%; 0.97)和最大cSUV (cSUVmax) (12%, P = 0.90; 0.96)或最大cSUR (cSURmax) (13%, P = 0.67; 0.94)之间的级内重复性(中位数测试-重复测试|%Δ|;ICC)没有差异。对于 DOTATATE-avid 病变(n = 23),Ki ,max (11%; 0.98) 与 cSUVmax (13%, P = 0.41; 0.98) 或 cSURmax (11%, P = 0.08; 0.94) 之间的扫描内重复性没有差异。SUVmax、cSUVmax、SURmax和cSURmax均与[18F]FDG(R 2,0.81-0.92)和DOTATATE(R 2,0.88-0.96)的Ki ,max密切相关,但cSURmax与[18F]FDG(ICC,0.69-0.75)和DOTATATE(ICC,0.90-0.91)从早到晚各时间点的Ki ,max的一致性最好。结论与 SUVmax 和 SURmax 相比,Ki ,max、cSUVmax 和 cSURmax 的摄取时间依赖性较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care. Is the Clinical Implementation of In-House Artificial Intelligence-Developed Algorithms Happening? Gastrin-Releasing Peptide Receptor Imaging and Therapy in the Era of Personalized Medicine. Maintaining the Evidence for In Vivo Brain Estrogen Receptor Density by Neuroendocrine Aging and Relationships with Cognition and Symptomatology. From Scientist to Analyst to Strategist: Aharon (Ronny) Gal Talks with Ken Herrmann and Johannes Czernin About Leadership in Multinational Pharma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1